Literature DB >> 15448912

[Treatment of sialorrhea with botulinum toxin: an overview].

J Hagenah1, K G Kahl, S Steinlechner, R Lencer, C Klein.   

Abstract

Hypersalivation (sialorrhea) is a common complaint of patients with neurodegenerative disorders such as Parkinson's disease or amyotrophic lateral sclerosis and a frequently disabling side effect of atypical antipsychotic drugs. Conventional treatment including oral anticholinergic or antihistamine medication is often limited by adverse effects and lack of efficacy. Over the past few years, several studies reported decreased drooling after injections of botulinum toxin into the salivary glands. This review describes the current state of treatment of sialorrhea with botulinum toxin.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15448912     DOI： 10.1007/s00115-004-1799-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  50 in total

1.  Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report.

Authors:  J Calderon; E Rubin; W L Sobota
Journal:  Int Clin Psychopharmacol       Date:  2000-01       Impact factor: 1.659

2.  Clonidine treatment of clozapine-induced hypersalivation.

Authors:  J Grabowski
Journal:  J Clin Psychopharmacol       Date:  1992-02       Impact factor: 3.153

3.  Amitriptyline in clozapine-induced sialorrhoea.

Authors:  P J Copp; R Lament; T G Tennent
Journal:  Br J Psychiatry       Date:  1991-07       Impact factor: 9.319

4.  The surgical treatment of drooling. A ten-year review.

Authors:  T F Wilkie; G S Brody
Journal:  Plast Reconstr Surg       Date:  1977-06       Impact factor: 4.730

5.  Submandibular duct relocation for drooling: a 10-year experience with 194 patients.

Authors:  W S Crysdale; A White
Journal:  Otolaryngol Head Neck Surg       Date:  1989-07       Impact factor: 3.497

6.  Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment--botulinum toxin A injections of the parotid glands.

Authors:  K O Bushara
Journal:  Med Hypotheses       Date:  1997-04       Impact factor: 1.538

7.  Treatment of blepharospasm with botulinum toxin. A preliminary report.

Authors:  B R Frueh; D P Felt; T H Wojno; D C Musch
Journal:  Arch Ophthalmol       Date:  1984-10

8.  Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.

Authors:  Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; Emilia Martignoni; Giuseppe Nappi; Claudio Pacchetti
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

9.  Botulinum toxin as an effective treatment of clozapine-induced hypersalivation.

Authors:  Kai G Kahl; Johann Hagenah; Silke Zapf; Peter Trillenberg; Christine Klein; Rebekka Lencer
Journal:  Psychopharmacology (Berl)       Date:  2004-01-28       Impact factor: 4.530

Review 10.  Molecular aspects of tetanus and botulinum neurotoxin poisoning.

Authors:  G Ahnert-Hilger; H Bigalke
Journal:  Prog Neurobiol       Date:  1995-05       Impact factor: 11.685
View more
  1 in total

1.  [Drooling following radiation. Botulinum toxin as a successful treatment modality].

Authors:  A Steffen; B Wollenberg; R Schönweiler; N Brüggemann; T Meyners
Journal:  HNO       Date:  2011-01       Impact factor: 1.284
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.